Lee Sterling, Reid Ashley, Tong Suhong, Silveira Lori, Thomas James J, Masaracchia Melissa M
University of Colorado School of Medicine (SL), Aurora, CO.
Department of Pharmacy (AR), University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, CO.
J Pediatr Pharmacol Ther. 2022;27(1):51-56. doi: 10.5863/1551-6776-27.1.51. Epub 2021 Dec 22.
Pediatric patients with sleep-disordered breathing (SDB) and obesity are at risk for opioid-induced respiratory depression. Although monitoring in the inpatient setting allows for early recognition of opioid-related adverse events, there is far less vigilance after ambulatory surgery as patients are discharged home. Guidelines for proper opioid dosing in these pediatric subsets have not been established. We sought to determine if at-risk children were more likely to receive doses of opioids outside the recommended range.
Baseline opioid prescribing data for all outpatient surgery patients receiving an opioid prescription between January 2019 and June 2020 were retrospectively reviewed. Patients with SDB or obesity were identified. To obtain more information about prescribing practices, we analyzed patient demographics, size descriptors used for calculations, and prescription characteristics (dose, duration, and prescribing surgical service).
A total of 4674 patients received an opioid prescription after outpatient surgery. Of those, 173 patients had SDB and 128 were obese. Surgical subspecialties rendering most of the opioid prescriptions included otolaryngology and orthopedics. Obese patients were more likely (64%) to be prescribed opioids using ideal weight at higher mg/kg doses (>0.05 mg/kg; 83.3%; p < 0.0001). When providers used actual body weight, lower mg/kg doses were more likely to be used (53.7%; p < 0.0001). No prescriptions used lean body mass.
Overweight/obese children were more likely to receive opioid doses outside the recommended range. Variability in prescribing patterns demonstrates the need for more detailed guidelines to minimize the risk of opioid-induced respiratory complications in vulnerable pediatric populations.
患有睡眠呼吸障碍(SDB)和肥胖的儿科患者有阿片类药物引起呼吸抑制的风险。尽管在住院环境中进行监测有助于早期识别与阿片类药物相关的不良事件,但门诊手术后患者出院回家时的警惕性要低得多。目前尚未制定针对这些儿科亚组的阿片类药物正确给药指南。我们试图确定高危儿童是否更有可能接受超出推荐范围的阿片类药物剂量。
回顾性分析了2019年1月至2020年6月期间所有接受阿片类药物处方的门诊手术患者的基线阿片类药物处方数据。识别出患有SDB或肥胖的患者。为了获取更多关于处方实践的信息,我们分析了患者人口统计学、用于计算的体型描述符以及处方特征(剂量、持续时间和开处方的手术科室)。
共有4674名患者在门诊手术后接受了阿片类药物处方。其中,173名患者患有SDB,128名患者肥胖。开出大多数阿片类药物处方的手术亚专业包括耳鼻喉科和骨科。肥胖患者更有可能(64%)按照理想体重以较高的mg/kg剂量(>0.05 mg/kg;83.3%;p<0.0001)开具阿片类药物。当医生使用实际体重时,更有可能使用较低的mg/kg剂量(53.7%;p<0.0001)。没有处方使用瘦体重。
超重/肥胖儿童更有可能接受超出推荐范围的阿片类药物剂量。处方模式的差异表明需要更详细的指南,以将弱势儿科人群中阿片类药物引起的呼吸并发症风险降至最低。